Anadis Opens New Approach to Respiratory Disease Control

kavin submitted, created time 2 months 3 weeks (www.medicalnewstoday.com)

Anadis Limited (ASX: ANX), a research-driven biopharmaceutical company focused on polyclonal antibodies to address human disease, announced important progress concerning its accelerated program to develop a nasal antibody spray to provide immediate post-exposure prophylaxis against a range of influenza viruses.

Working with an animal influenza challenge model in the laboratory of Professor Loreena Brown at the Department of Microbiology and Immunology, University of Melbourne, scientists successfully completed a series of proof-in-principal experiments

3 comments | Blog It | Email It | Keywords: antibodies drug discovery the flu influenza influenza A viruses influenza A virus influenza B virus avian influenza virus

Structural basis for receptor specificity of influenza B virus hemagglutinin

franklin submitted, created time 1 year 1 month (www.pnas.org)

Receptor-binding specificity of HA, the major surface glycoprotein of influenza virus, primarily determines the host ranges that the virus can infect. Influenza type B virus almost exclusively infects humans and contributes to the annual "flu" sickness.

Submit comment | Blog It | Email It | Keywords: receptor specificity influenza B virus surface glycoprotein